Vis enkel innførsel

dc.contributor.authorSolmi, Marco
dc.contributor.authorMiola, Alessandro
dc.contributor.authorCapone, Federico
dc.contributor.authorPallottino, Simone
dc.contributor.authorHøjlund, Mikkel
dc.contributor.authorFirth, Joseph
dc.contributor.authorSiskind, Dan
dc.contributor.authorHolt, Richard IG
dc.contributor.authorCorbeil, Olivier
dc.contributor.authorCortese, Samuele
dc.contributor.authorDragioti, Elena
dc.contributor.authorRietz, Ebba Du
dc.contributor.authorNielsen, Rene Ernst
dc.contributor.authorNordentoft, Merete
dc.contributor.authorFusar-Poli, Paolo
dc.contributor.authorHartman, Catharina A
dc.contributor.authorHøye, Anne
dc.contributor.authorKoyanagi, Ai
dc.contributor.authorLarsson, Henrik
dc.contributor.authorLehto, Kelli
dc.contributor.authorLindgren, Peter
dc.contributor.authorManchia, Mirko
dc.contributor.authorSkonieczna-Żydecka, Karolina
dc.contributor.authorStubbs, Brendon
dc.contributor.authorVancampfort, Davy
dc.contributor.authorVieta, Eduard
dc.contributor.authorTaipale, Heidi
dc.contributor.authorCorrell, Cristoph U.
dc.date.accessioned2025-03-18T10:08:42Z
dc.date.available2025-03-18T10:08:42Z
dc.date.issued2024-09-23
dc.description.abstractIntroduction - People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.<p> <p>Areas covered - We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.<p> <p>Expert opinion - To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications’ and patient’s weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.en_US
dc.identifier.citationSolmi, Miola, Capone, Pallottino, Højlund, Firth, Siskind, Holt, Corbeil, Cortese, Dragioti, Rietz, Nielsen, Nordentoft, Fusar-Poli, Hartman, Høye, Koyanagi, Larsson, Lehto, Lindgren, Manchia, Skonieczna-Żydecka, Stubbs, Vancampfort, Vieta, Taipale, Correll. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review. Expert Opinion on Drug Safety. 2024en_US
dc.identifier.cristinIDFRIDAID 2286835
dc.identifier.doi10.1080/14740338.2024.2396396
dc.identifier.issn1474-0338
dc.identifier.issn1744-764X
dc.identifier.urihttps://hdl.handle.net/10037/36712
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalExpert Opinion on Drug Safety
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.titleRisk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical reviewen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel